CO55 Incidence of Adverse Events with Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review of Literature
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.144
https://www.valueinhealthjournal.com/article/S1098-3015(24)00259-6/fulltext
Title :
CO55 Incidence of Adverse Events with Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review of Literature
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00259-6&doi=10.1016/j.jval.2024.03.144
First page :
Section Title :
Open access? :
No
Section Order :
10819